XML Financial LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 17.4% during the first quarter, Holdings Channel reports. The institutional investor owned 1,758 shares of the company’s stock after acquiring an additional 261 shares during the period. XML Financial LLC’s holdings in Eli Lilly and Company were worth $1,367,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of Eli Lilly and Company by 1.8% during the 1st quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after purchasing an additional 13 shares during the last quarter. Innova Wealth Partners lifted its stake in shares of Eli Lilly and Company by 1.2% during the first quarter. Innova Wealth Partners now owns 1,068 shares of the company’s stock valued at $831,000 after buying an additional 13 shares during the period. Moseley Investment Management Inc. boosted its position in Eli Lilly and Company by 0.4% during the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares during the last quarter. CGN Advisors LLC grew its stake in Eli Lilly and Company by 1.4% in the 1st quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after acquiring an additional 14 shares during the period. Finally, Twin Peaks Wealth Advisors LLC raised its holdings in Eli Lilly and Company by 2.0% in the 1st quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock valued at $559,000 after acquiring an additional 14 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Stock Performance
LLY traded up $28.17 on Thursday, hitting $832.44. 3,996,057 shares of the company’s stock were exchanged, compared to its average volume of 2,998,226. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a fifty day moving average of $870.37 and a two-hundred day moving average of $786.41. Eli Lilly and Company has a twelve month low of $446.89 and a twelve month high of $966.10. The firm has a market cap of $791.16 billion, a PE ratio of 121.83, a P/E/G ratio of 1.72 and a beta of 0.41.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on LLY shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,001.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Truist Financial reissued a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a research report on Friday, July 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $858.72.
View Our Latest Report on Eli Lilly and Company
Insider Transactions at Eli Lilly and Company
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,214,704 shares of company stock worth $1,066,841,316. Insiders own 0.13% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- First Solar Stock: The Dawn of a New Rally in Share Prices
- Health Care Stocks Explained: Why You Might Want to Invest
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Learn Technical Analysis Skills to Master the Stock Market
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.